2200 Bridge Pkwy
Redwood City, CA 94065
650 549 1400
Full Time Employees: 35
|Dr. Judith Anne Shizuru M.D., Ph.D.||Co-Founder, Chair of Scientific Advisory Board & Director||260.77k||N/A||1957|
|Mr. Jeetinder Singh Mahal M.B.A.||CFO, COO & Corp. Sec.||461.12k||N/A||1973|
|Dr. Kevin N. Heller M.D.||Exec. VP of R&D||617.99k||N/A||1972|
|Mr. Ronald A. Martell||Pres, CEO & Director||N/A||N/A||1962|
|Dr. Susan Prohaska Ph.D.||Co-Founder and VP of Operations & Program Management||N/A||N/A||N/A|
|Dr. Carol Zoltowski||Sr. VP of Regulatory Affairs & Quality||N/A||N/A||1950|
|Dr. Wendy Pang M.D., Ph.D.||Sr. VP of Research & Translational Medicine||N/A||N/A||N/A|
|Dr. Daniel C. Adelman M.D.||Acting Chief Medical Officer||N/A||N/A||1957|
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.